Dermata Therapeutics changes auditor to Baker Tilly after Moss Adams merger

Dermata Therapeutics, Inc.

Moss Adams merged into Baker Tilly US, LLP effective June 3, 2025; audit committee approved Baker Tilly as successor.
No disagreements with Moss Adams on accounting principles or audit scope for FY2024, FY2023, or interim period.
Prior audit reports included a going concern uncertainty paragraph; no adverse or modified opinions.
Moss Adams provided a letter agreeing with the statements, filed as Exhibit 16.1.

item 4.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.